Literature DB >> 16772533

WW domain binding protein-2, an E6-associated protein interacting protein, acts as a coactivator of estrogen and progesterone receptors.

Sarath C Dhananjayan1, Sivapriya Ramamoorthy, Obaid Y Khan, Ayesha Ismail, Jun Sun, Joyce Slingerland, Bert W O'Malley, Zafar Nawaz.   

Abstract

WW domain binding protein-2 (WBP-2) was cloned as an E6-associated protein interacting protein, and its role in steroid hormone receptors functions was investigated. We show that WBP-2 specifically enhanced the transactivation functions of progesterone receptor (PR) and estrogen receptor (ER), whereas it did not have any significant effect on the androgen receptor, glucocorticoid receptor, or the activation functions of p53 and VP-16. Depletion of endogenous WBP-2 with small interfering RNAs indicated that WBP-2 was required for the proper functioning of PR and ER. We also demonstrated that WBP-2 contains an intrinsic activation domain. Moreover, chromatin immunoprecipitation assays demonstrate the hormone-dependent recruitment of WBP-2 onto an estrogen-responsive promoter. Mutational analysis suggests that one of three polyproline (PY) motifs of WBP-2 is essential for its coactivation and intrinsic activation functions. We show that WBP-2 and E6-associated protein each enhance PR function, and their effect on PR action are additive when coexpressed, suggesting a common signaling pathway. In this study, we also demonstrate that the WBP-2 binding protein, Yes kinase-associated protein (YAP) enhances PR transactivation, but YAP's coactivation function is absolutely dependent on WBP-2. Taken together, our data establish the role of WBP-2 and YAP as coactivators for ER and PR transactivation pathways.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16772533     DOI: 10.1210/me.2005-0533

Source DB:  PubMed          Journal:  Mol Endocrinol        ISSN: 0888-8809


  42 in total

1.  Differential modulation of glucocorticoid and progesterone receptor transactivation.

Authors:  Daniele Szapary; Liang-Nian Song; Yuangzheng He; S Stoney Simons
Journal:  Mol Cell Endocrinol       Date:  2007-12-08       Impact factor: 4.102

2.  Biophysical analysis of binding of WW domains of the YAP2 transcriptional regulator to PPXY motifs within WBP1 and WBP2 adaptors.

Authors:  Caleb B McDonald; Samantha K N McIntosh; David C Mikles; Vikas Bhat; Brian J Deegan; Kenneth L Seldeen; Ali M Saeed; Laura Buffa; Marius Sudol; Zafar Nawaz; Amjad Farooq
Journal:  Biochemistry       Date:  2011-10-14       Impact factor: 3.162

Review 3.  WWP1: a versatile ubiquitin E3 ligase in signaling and diseases.

Authors:  Xu Zhi; Ceshi Chen
Journal:  Cell Mol Life Sci       Date:  2011-11-04       Impact factor: 9.261

4.  The transcriptional coactivator WBP2 primes triple-negative breast cancer cells for responses to Wnt signaling via the JNK/Jun kinase pathway.

Authors:  Zilin Li; Shen Kiat Lim; Xu Liang; Yoon Pin Lim
Journal:  J Biol Chem       Date:  2018-11-15       Impact factor: 5.157

5.  Expression analysis of PAWP during mouse embryonic stem cell-based spermatogenesis in vitro.

Authors:  Seyedmehdi Nourashrafeddin; Mahmoud Aarabi; Mohammad Miryounesi; Reza Ebrahimzadeh-Vesal; Nosratollah Zarghami; Mohammad Hosein Modarressi; Mohammad Nouri
Journal:  In Vitro Cell Dev Biol Anim       Date:  2014-01-01       Impact factor: 2.416

6.  Kinase-independent feedback of the TAK1/TAB1 complex on BCL10 turnover and NF-κB activation.

Authors:  Miguel E Moreno-García; Karen Sommer; Hector Rincon-Arano; Michelle Brault; Jun Ninomiya-Tsuji; Lydia E Matesic; David J Rawlings
Journal:  Mol Cell Biol       Date:  2013-01-07       Impact factor: 4.272

7.  Wbp2 cooperates with Yorkie to drive tissue growth downstream of the Salvador-Warts-Hippo pathway.

Authors:  X Zhang; C C Milton; C L C Poon; W Hong; K F Harvey
Journal:  Cell Death Differ       Date:  2011-02-11       Impact factor: 15.828

Review 8.  Decoding the link between WWOX and p53 in aggressive breast cancer.

Authors:  Suhaib K Abdeen; Rami I Aqeilan
Journal:  Cell Cycle       Date:  2019-05-16       Impact factor: 4.534

9.  Inhibition of the Rho GTPase, Rac1, decreases estrogen receptor levels and is a novel therapeutic strategy in breast cancer.

Authors:  Adena E Rosenblatt; Maria Ines Garcia; Leah Lyons; Yingqiu Xie; Carol Maiorino; Laurent Désiré; Joyce Slingerland; Kerry L Burnstein
Journal:  Endocr Relat Cancer       Date:  2011-02-23       Impact factor: 5.678

10.  E6AP in the brain: one protein, dual function, multiple diseases.

Authors:  Jimmy El Hokayem; Zafar Nawaz
Journal:  Mol Neurobiol       Date:  2013-10-05       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.